|Product Overview:||Recombinant Human LGALS9(Ala2-Thr323) was expressed in E. coli.|
|Description:||Galectins comprise a family of multifunctional carbohydrate-binding proteins with specificity for N‑acetyl-lactosamine-containing glycoproteins. At least 14 mammalian Galectins share structural similarities in their carbohydrate recognition domains (CRD), forming three groups: prototype (one CRD), tandem-repeat (two CRDs), and chimeric (one CRD, unique N‑terminus). Full length Galectin-9 is a widely expressed 39 kDa tandem-repeat Galectin that contains two CRDs connected by a linker region. Progressive deletion within the linker region generates a 36 kDa isoform, also known as Ecalectin or UAT, as well as a 35 kDa isoform. This recombinant protein corresponds to the Ecalectin isoform of human Galectin-9 and shares 70% and 73% aa sequence identity with the corresponding regions of mouse and rat Galectin-9, respectively. Galectin-9 exhibits a wide range of activities. All three isoforms function as eosinophil chemoattractants. This activity is destroyed by thrombin-mediated cleavage within the linker region of the long isoform, although the Ecalectin isoform is resistant to thrombin. Galectin-9 binds to carbohydrate moieties of IgE, thereby preventing immune complex formation, mast cell degranulation, and asthmatic and cutaneous anaphylaxis reactions. Independent of its lectin properties, Galectin-9 induces the maturation of dendritic cells which promote Th1 polarization. Galectin-9 induces cellular apoptosis in part by direct binding to TIM-3. Its interaction with TIM-3 inhibits Th1 cell and CD8+ cytotoxic T cell responses and also promotes regulatory T cell differentiation and activity. Galectin-9 suppresses tumor cell metastasis by interfering with the associations between hyaluronic acid and CD44 and between VCAM-1 and Integrin alpha 4 beta 1. The Ecalectin isoform (UAT; urate transporter) can also be expressed as an integral membrane protein and mediate the cellular efflux of urate.|
|Predicted N Terminal:||Ala2|
|Form:||Lyophilized from a 0.2 μm filtered solution in MOPS, NaCl, EDTA, DTT and Trehalose.|
|Bio-activity:||Measured by its ability to induce apoptosis of Jurkat human acute T cell leukemia cells. Lu, L.H. et al. (2007) J. Biochem. 141:157. The ED50 for this effect is typically 1-5 μg/mL. Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human Galectin-9 at 500 ng/mL can bind Recombinant Human TIM-3 Fc Chimera with an apparent Kd <30 nM. Measured by its ability to agglutinate human red blood cells. Hadari, Y.R. et al. (2000) J. Cell Sci. 113:2385. The ED50 for this effect is typically 2.5‑12.5 µg/mL.|
|Molecular Mass:||Predicted Molecular Mass: 35.8 kDa
SDS-PAGE: 34 kDa, reducing conditions
|Endotoxin:||<0.1 EU per 1 μg of the protein by the LAL method.|
|Purity:||>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.|
|Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
|Reconstitution:||Reconstitute at 100 μg/mL in water.|
|Gene Name:||LGALS9 lectin, galactoside-binding, soluble, 9 [ Homo sapiens ]|
|Synonyms:||LGALS9; lectin, galactoside-binding, soluble, 9; galectin-9; galectin 9; LGALS9A; gal-9; ecalectin; tumor antigen HOM-HD-21; urate transporter/channel protein; HUAT; MGC117375; MGC125973; MGC125974;|
Price does not include shipping and packaging costs.Request quote for final price.